Market News (Page 4) - TendieTensor

Market News Page 4 of 283 • 7,066 articles

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)

GlobeNewswire Inc. • Inspiremd, Inc.

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)

01/12/2026 09:00 AM • InspireMD announced that its C-GUARDIANS pivotal trial results have been published in JACC, demonstrating that the CGuard® Prime Carotid Stent System achieved the lowest 30-day and 1-year major adverse event rates in carotid stenting studies, with a 30-day DSMI rate of 0.95% and 1-year ipsilateral stroke rate of 1.93%. The trial enrolled 316 patients including 25% symptomatic cases, showing strong safety and efficacy data for carotid artery stenosis treatment.

STZ - Down 40% in 2025 but with significant analyst price target upside, low forward earnings multiple, and diverse beverage portfolio
NSPR - The company announced positive pivotal trial results published in a top-tier medical journal (JACC), demonstrating superior safety outcomes (lowest event rates in the industry) for its flagship product CGuard® Prime. The publication in a prestigious journal and achievement of primary endpoints with historically low complication rates represent significant validation and should support future adoption and revenue growth.

#carotid stenting #CGuard Prime #clinical trial results #stroke prevention #FDA approval #medical device #interventional cardiology

Oriental Culture Holding LTD Announces Special Cash Dividend Plan to Reward Shareholders on Fifth Anniversary of Listing

Benzinga • Prnewswire

Oriental Culture Holding LTD Announces Special Cash Dividend Plan to Reward Shareholders on Fifth Anniversary of Listing

01/12/2026 08:55 AM • Oriental Culture Holding (NASDAQ: OCG) announced a special cash dividend of $0.05 per share to celebrate its fifth anniversary of listing on Nasdaq. The dividend will be paid on February 9, 2026, to shareholders of record as of January 22, 2026. CEO Shao Yi stated the company is returning accumulated cash reserves to shareholders as a reward for their long-term support and to foster long-term value creation.

OCG - The announcement of a special cash dividend demonstrates financial strength and management's commitment to returning value to shareholders. The dividend payment indicates the company has sufficient cash reserves after funding operations, which is a positive signal of financial health and confidence in the business.

#special cash dividend #fifth anniversary #shareholder reward #Nasdaq listing #cash reserves

LightPath Technologies to Participate in the 28th Annual Needham Growth Conference on January 15, 2026

Benzinga • Prnewswire

LightPath Technologies to Participate in the 28th Annual Needham Growth Conference on January 15, 2026

01/12/2026 08:31 AM • LightPath Technologies (NASDAQ:LPTH) announced it will participate in the 28th Annual Needham Growth Conference on January 15, 2026, hosting one-on-one virtual meetings with institutional investors. The company highlighted its strengthened balance sheet following a recent financing and plans to discuss its defense and commercial optics platforms and strategic priorities.

LPTH - The company is actively engaging with institutional investors at a major growth conference, recently completed successful financing, and management expressed confidence in advancing strategic priorities and creating shareholder value. The tone is optimistic about market opportunities and the company's strengthened financial position.

#LightPath Technologies #Needham Growth Conference #optics and imaging systems #defense applications #commercial applications #investor meetings #balance sheet #infrared optical systems

Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.)

GlobeNewswire Inc. • Orion Corporation

Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.)

01/12/2026 08:00 AM • BlackRock, Inc. and its funds have exceeded the 5% ownership threshold in Orion Corporation, reaching a combined 5.01% stake as of January 9, 2026. The holding consists of 4.97% in direct shares (7,014,577 shares) and 0.04% through financial instruments including American Depositary Receipts and borrowed securities.

NSRGY - Mentioned as the seller of the infant formula plant and brand rights, with no direct negative implications in the lawsuit
BLK - The disclosure is a regulatory announcement of BlackRock crossing the 5% ownership threshold in Orion. This is a factual reporting of shareholding changes with no inherent positive or negative implications. It represents a significant investment position but does not indicate strategic intent or market impact.

#major shareholder disclosure #ownership threshold #BlackRock #Orion Corporation #5% stake #financial instruments #Securities Market Act

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

GlobeNewswire Inc. • Na

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

01/12/2026 08:00 AM • MDxHealth reported preliminary 2025 revenues of $109 million (21% YoY growth) with Q4 revenues of $30.5 million (23% YoY growth). The company issued 2026 revenue guidance of $137-140 million (26-28% growth) and expects to achieve a 10% adjusted EBITDA margin run rate by year-end 2026. MDxHealth amended its earnout obligations with Exact Sciences, deferring payments to 2026-2028 and issuing 3 million warrant shares at $5.265 per share.

EXAS - Exact Sciences benefited from earnout amendment deferring payments and receiving 3 million warrant shares, providing liquidity relief to MDxHealth. The amendment is mutually beneficial but represents a restructuring of original acquisition terms rather than new positive developments.

#precision diagnostics #prostate cancer testing #revenue growth #2026 guidance #earnout amendment #liquid-based units #tissue-based units #EBITDA margin #GPS test #ExoDx

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

GlobeNewswire Inc. • Orion Corporation Communications

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

01/12/2026 08:00 AM • BlackRock, Inc. and its funds have crossed the 5% ownership threshold in Orion Corporation as of January 9, 2026, holding 5.01% of total shares and voting rights (7,014,577 direct shares plus 57,180 shares through financial instruments). This disclosure was made under Chapter 9, Section 10 of the Securities Market Act.

BLK - The disclosure is a factual regulatory announcement of BlackRock crossing the 5% ownership threshold in Orion. While this indicates significant investment interest, the announcement itself is neutral in tone and is a standard regulatory filing with no indication of positive or negative implications for either party.

#major shareholder disclosure #5% threshold #ownership stake #BlackRock #Orion Corporation #Securities Market Act #voting rights

U.S. Mental Health Treatment Market Report and Directory 2026, Profiles of Acadia, Universal Health Services, Lyra Health, Spring Health, Headspace, Calm, Talkspace, BetterHelp, Carelon

GlobeNewswire Inc. • Marketdata Llc

U.S. Mental Health Treatment Market Report and Directory 2026, Profiles of Acadia, Universal Health Services, Lyra Health, Spring Health, Headspace, Calm, Talkspace, BetterHelp, Carelon

01/12/2026 07:59 AM • The U.S. mental health treatment market is valued at $118 billion and is projected to grow significantly through 2030, driven by increased awareness, technology integration, and rising mental illness prevalence affecting 61 million Americans. The sector faces challenges including a shortage of mental health professionals and access gaps, while teletherapy and mental health apps have created a $2 billion market segment. Major players include facility operators like Acadia Healthcare and Universal Health Services, alongside digital platforms such as Lyra Health, Spring Health, Headspace, Calm, Talkspace, and BetterHelp.

ACHC - Identified as a major industry leader in facility operations with strong market position in the growing $118 billion mental health treatment market

#mental health market #teletherapy #mental health apps #behavioral health #therapist shortage #digital health platforms #psychiatric care

Transactions in connection with share buyback programme

GlobeNewswire Inc. • Netcompany Group A/S

Transactions in connection with share buyback programme

01/12/2026 07:56 AM • Netcompany Group A/S executed 66,000 share buybacks during the week of 5-9 January 2026 at an average price of DKK 361.99, bringing total accumulated buybacks to 1,443,896 shares worth DKK 411.1m. The company now holds 1,801,415 treasury shares (3.8% of share capital) following the transactions and vesting of restricted share units. The buyback programme, initiated on 14 August 2025 with a budget of DKK 500m and maximum 3.7m shares, will conclude by 30 January 2026.

NETGY - The share buyback programme is a routine capital management activity executed in compliance with regulations. The consistent execution of buybacks at stable prices (DKK 351-367 range) and progress toward programme targets indicates orderly, planned financial management. No material business developments or concerns are indicated, making this a neutral operational announcement.

#share buyback #treasury shares #capital structure #share-based incentive programmes #Market Abuse Regulation #Nasdaq Copenhagen

Global Catheters Market Size to Hit USD 55.58 Billion by 2033, Driven by Rising Cardiovascular and Urological Procedures – SNS Insider

GlobeNewswire Inc. • Sns Insider

Global Catheters Market Size to Hit USD 55.58 Billion by 2033, Driven by Rising Cardiovascular and Urological Procedures – SNS Insider

01/12/2026 07:52 AM • The global catheters market is projected to grow from USD 29.17 billion in 2025 to USD 55.58 billion by 2033, with a CAGR of 8.41%. Growth is driven by increasing cardiovascular and urological procedures, aging populations, and technological advancements. However, catheter-associated infections and antibiotic resistance pose challenges. North America dominates with 38.05% market share, while Asia Pacific is the fastest-growing region at 9.23% CAGR.

CPB - Stock down 26% in 2025, but shows potential bullish reversal with analyst price target suggesting upside
MDT - Company is advancing its APOLLO trial for the Intrepid TMVR device with over 2,500 patient enrollments, demonstrating active innovation and market expansion in transcatheter mitral valve replacement therapy.

#catheters market #cardiovascular procedures #urological procedures #minimally invasive procedures #medical devices #healthcare infrastructure #catheter-associated infections #antimicrobial coatings #silicone catheters #homecare settings

Biomedical and ICT Convergence Market Research Report 2025-2030: Opportunities in Developing Connected Medical Devices, Enhancing Precision Medicine, and Improving Healthcare Delivery

GlobeNewswire Inc. • Researchandmarkets.Com

Biomedical and ICT Convergence Market Research Report 2025-2030: Opportunities in Developing Connected Medical Devices, Enhancing Precision Medicine, and Improving Healthcare Delivery

01/12/2026 07:50 AM • A comprehensive market research report analyzing the convergence of Information and Communications Technology (ICT) and biomedical sciences through 2030. The report highlights opportunities in connected medical devices, precision medicine, and healthcare delivery optimization, driven by the need to address rising healthcare costs while improving patient outcomes through real-time monitoring and data-driven personalized treatments.

GIS - Strong baking season potential, parent of iconic brands like Pillsbury, trading at attractive 10x earnings with analyst price target indicating significant upside
ABT - Listed as a key company in the biomedical and ICT convergence market, positioned to benefit from growing demand for connected medical devices and diagnostic solutions.

#biomedical technology #ICT convergence #connected medical devices #precision medicine #healthcare delivery #IoT healthcare #wearable devices #telemedicine #personalized treatment #healthcare economics

Rumble Secures Exclusive Video and Live Streaming Rights for The Dan Bongino Show

GlobeNewswire Inc. • Not Specified

Rumble Secures Exclusive Video and Live Streaming Rights for The Dan Bongino Show

01/12/2026 07:47 AM • Rumble Inc. has secured an exclusive video and live streaming distribution agreement with The Dan Bongino Show, which will relaunch on February 2, 2026. The show will stream weekdays for two hours on Rumble exclusively, with audio versions available on major podcast platforms. Westwood One will handle advertising sales for the program.

MKC - Strongest revenue quarter historically, stable dividend with 38-year increase streak, attractive valuation with potential 21% upside
RUM - Rumble secured an exclusive high-profile content deal with a major media personality, strengthening its platform's content library and competitive positioning. The CEO highlighted this as marking 'a new era' for the platform ahead of the 2026 midterms, indicating strategic growth and increased user engagement potential.

#Rumble Inc. #Dan Bongino Show #exclusive distribution agreement #video streaming #podcasting #Westwood One #independent media

Valuation Implications of Domestic Rare Earth Supply Chain Reshoring Corporate Analysis Report 2025: MP Materials and Lynas Positioned for Growth Via Governmental Backing and Strategic Offtake Agreements

GlobeNewswire Inc. • Researchandmarkets.Com

Valuation Implications of Domestic Rare Earth Supply Chain Reshoring Corporate Analysis Report 2025: MP Materials and Lynas Positioned for Growth Via Governmental Backing and Strategic Offtake Agreements

01/12/2026 07:46 AM • A new market analysis report examines opportunities in reshoring rare earth supply chains to reduce Western dependency on China, which controls 85-90% of global refined production. The report identifies MP Materials and Lynas as key beneficiaries positioned for growth through government backing and strategic offtake agreements, with domestic suppliers potentially commanding 250-350% price premiums over Chinese benchmarks due to security considerations.

MKC.V - Strongest revenue quarter historically, stable dividend with 38-year increase streak, attractive valuation with potential 21% upside
MP - Identified as the leading U.S. rare earth producer with the only fully integrated U.S. mine-to-magnet operation at Mountain Pass. Positioned as a primary beneficiary of government backing, strategic offtake agreements with major customers (GM, Apple), and security premium valuations.

#rare earth elements #supply chain reshoring #geopolitical risk #domestic production #national security #China dependency #critical minerals #defense technology #green energy transition

First Watch Restaurant Group, Inc. Reports Preliminary Operational Metrics for the Fourth Quarter and Fiscal Year 2025

GlobeNewswire Inc. • First Watch Restaurant Group, Inc.

First Watch Restaurant Group, Inc. Reports Preliminary Operational Metrics for the Fourth Quarter and Fiscal Year 2025

01/12/2026 07:00 AM • First Watch reported strong 2025 performance with 64 new restaurant openings across 23 states, same-restaurant sales growth of +3.6%, and positive same-restaurant traffic growth of +0.5%. The company ended the year with 633 system-wide restaurants across 32 states and expressed confidence in its long-term strategy and 2026 pipeline.

FWRG - The company demonstrated strong operational performance with record 64 new restaurant openings in 2025, positive same-restaurant sales growth of +3.6%, positive same-restaurant traffic growth of +0.5%, and a strong pipeline for 2026. New restaurant classes are outperforming expectations and the comparable restaurant base, indicating healthy business momentum and successful execution of growth strategy.

#restaurant expansion #same-restaurant sales growth #daytime dining #new openings #operational metrics #franchise growth #traffic growth

RAD Increases Ownership in Radiopharm Ventures to 87.5%

GlobeNewswire Inc. • Not Specified

RAD Increases Ownership in Radiopharm Ventures to 87.5%

01/12/2026 07:00 AM • Radiopharm Theranostics increased its ownership stake in Radiopharm Ventures (joint venture with MD Anderson Cancer Center) from 75% to 87.5%. The leading candidate Betabart, a B7H3-targeting monoclonal antibody, received FDA IND clearance and is expected to dose the first patient in Q1 2026 in a Phase I trial for solid tumors. Two additional preclinical assets show early positive results with final candidate selection planned for 2026.

SHOP - Mentioned in context of beta-testing Managed Markets flow without detailed performance information
RADX - Company increased ownership stake in promising joint venture, lead candidate received FDA IND clearance, first-in-human trial expected to begin Q1 2026, and additional preclinical candidates showing positive results. These developments indicate strong pipeline progress and confidence in the program's potential.

#radiopharmaceuticals #oncology #B7H3 #Betabart #monoclonal antibody #Phase I trial #FDA IND clearance #joint venture #MD Anderson Cancer Center #solid tumors

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

GlobeNewswire Inc. • Na

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

01/12/2026 07:00 AM • Lexeo Therapeutics reported positive interim Phase I/II data for LX2020, an AAV-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy. The therapy demonstrated good tolerability across 10 participants, with 93-162% increases in PKP2 protein expression and stabilization or improvement in arrhythmia burden in the majority of participants. The company plans to complete 12-month data collection by Q4 2026 and engage with regulators in 2026.

TPR - Noted as a new partner in UK and Europe without specific performance context
LXEO - The company announced positive interim clinical trial data showing good safety profile, robust transduction, meaningful increases in PKP2 protein expression (93-162%), and clinically meaningful improvement or stabilization in arrhythmia burden across the majority of participants. No serious safety concerns were reported, and the therapy addresses an unmet medical need in a rare disease affecting approximately 60,000 people in the US.

#gene therapy #AAV #arrhythmogenic cardiomyopathy #PKP2 #Phase I/II trial #cardiac disease #protein expression #clinical trial data

Amplify ETFs Nominated for ETF Provider of the Year

GlobeNewswire Inc. • Na

Amplify ETFs Nominated for ETF Provider of the Year

01/12/2026 07:00 AM • Amplify ETFs announced four nominations across three categories in the With Intelligence Mutual Fund and ETF Awards, including ETF Provider of the Year. The company's blockchain, junior silver miners, and growth & income ETFs were recognized for their performance and innovation. Winners will be announced on February 11, 2026.

BLOK - BLOK received a nomination for Alternative ETF of the Year and holds a 5-star Morningstar rating. The fund demonstrated exceptional performance with 32.95% YTD return and 269.59% return since inception, positioning it as an early leader in blockchain investment exposure.

#ETF awards #Amplify ETFs #blockchain ETF #silver miners ETF #covered call options #asset management #investment performance

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc. • Apellis Pharmaceuticals, Inc.

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

01/12/2026 07:00 AM • Apellis Pharmaceuticals reported preliminary full-year 2025 U.S. net product revenues of $689 million, driven by strong performance from SYFOVRE (geographic atrophy treatment) at $587 million and EMPAVELI (kidney disease treatment) at $102 million. SYFOVRE achieved 60% market share with 17% year-over-year injection growth, while EMPAVELI reached over 5% market penetration in its target indications within five months of launch. The company maintains approximately $466 million in cash and expects to reach profitability through product revenues.

DIS - Mentioned as a recipient of Chinese bank credit lines without specific negative or positive implications
APLS - Strong commercial execution with $689M in 2025 revenues, SYFOVRE achieving 60% market leadership with 17% YoY growth, EMPAVELI exceeding 5% market penetration in just 5 months post-launch, rapid payer uptake at 95%, positive Phase 3 data published in NEJM, pipeline expansion into additional indications (FSGS, DGF), and sufficient cash position ($466M) to fund operations to profitability.

#SYFOVRE #EMPAVELI #geographic atrophy #C3G #IC-MPGN #complement inhibitor #clinical trial #FDA approval #revenue growth #market penetration

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

GlobeNewswire Inc. • Na

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

01/12/2026 07:00 AM • Axogen reported preliminary full-year 2025 revenue of approximately $225.2 million, representing 20.2% growth over 2024, with Q4 2025 revenue expected at $59.9 million (21.3% increase). The company achieved FDA Biologics License Application approval for Avance® on December 3, 2025, and expects gross margins above 74%. Cash position improved by approximately $6.0 million to $45.5 million by year-end 2025.

QCOM - Mentioned as a recipient of Chinese bank credit lines without specific negative or positive implications
AXGN - Strong revenue growth of 20.2% year-over-year, significant FDA BLA approval milestone for Avance®, improved cash position, gross margins above 74%, and positive momentum across business functions support confidence in strategic execution and future growth prospects.

#peripheral nerve repair #FDA approval #BLA #revenue growth #Avance® #gross margin #commercial strategy #medical devices

Gaming and Leisure Properties, Inc. Schedules Fourth Quarter 2025 Earnings Release and Conference Call

GlobeNewswire Inc. • Na

Gaming and Leisure Properties, Inc. Schedules Fourth Quarter 2025 Earnings Release and Conference Call

01/12/2026 07:00 AM • Gaming and Leisure Properties, Inc. (NASDAQ: GLPI) announced it will release its 2025 fourth quarter financial results on February 19, 2026, followed by a conference call on February 20, 2026, where Chairman and CEO Peter M. Carlino and senior management will review quarterly results and performance.

BApA - Mentioned as a recipient of Chinese bank credit lines without specific negative or positive implications
GLPI - The article is a routine announcement of earnings release and conference call scheduling. It contains no information about financial performance, business developments, or market conditions that would indicate positive or negative sentiment. It is purely procedural in nature.

#earnings release #fourth quarter 2025 #conference call #financial results #real estate #gaming operators #triple-net lease

Five Below, Inc. Announces Holiday Sales Results for Quarter-To-Date Through January 3, 2026

GlobeNewswire Inc. • Na

Five Below, Inc. Announces Holiday Sales Results for Quarter-To-Date Through January 3, 2026

01/12/2026 07:00 AM • Five Below announced strong holiday period results with net sales increasing 23.2% to $1.47 billion and comparable sales growth of 14.5%. Based on this performance, the company raised its full year fiscal 2025 outlook, projecting net sales of approximately $4.75 billion with comparable sales increase of 12.5% and adjusted diluted EPS of $6.30 to $6.35.

BA - Mentioned as a recipient of Chinese bank credit lines without specific negative or positive implications
FIVE - The company exceeded expectations with strong holiday sales growth of 23.2%, solid comparable sales increase of 14.5%, and proactively raised full year guidance. CEO commentary highlights successful strategy execution, strong team performance, and confidence in 2026 opportunities. The company demonstrated broad-based results and improved customer journey initiatives.

#holiday sales #comparable sales growth #earnings outlook #retail performance #customer experience #inventory management #tariffs

Markets Week Ahead: Key Bank Earnings, Inflation Data Take Center Stage

Investing.com • Ali Merchant

Markets Week Ahead: Key Bank Earnings, Inflation Data Take Center Stage

01/12/2026 06:31 AM • Bank earnings season kicks off this week with major financial institutions reporting results amid geopolitical tensions and Fed uncertainty. December CPI data will be crucial for the Fed's rate outlook. Gold hit record highs above $4,600/oz due to Iran unrest and concerns over Fed independence following DOJ subpoenas. Oil rallied on Iran protests, while US stocks opened 2026 strongly despite political risks.

AUUDW - Company is expanding user base, making premium features free, and developing innovative AI technology for music discovery and artist promotion
AMJB - Major bank reporting earnings this week; stock near record highs but under pressure to impress. No specific positive or negative catalysts mentioned.

#bank earnings #Q4 earnings #December CPI #Fed subpoenas #gold prices #Iran protests #oil rally #geopolitical tensions #interest rates #inflation data

Teladoc Health Launches Enhanced 24/7 Care Service

GlobeNewswire Inc. • Lou Serio

Teladoc Health Launches Enhanced 24/7 Care Service

01/12/2026 06:00 AM • Teladoc Health announced enhancements to its 24/7 Care virtual urgent care service, expanding treatment capabilities to include a broader range of conditions, enabling specialist consultations during visits, improving preventive care detection, and allowing real-time prescription benefit checks. The service now reaches over 100 million Americans and demonstrates high member satisfaction with 95% of concerns addressed in single visits.

TDOC - The company announced significant service enhancements that expand clinical capabilities, improve member outcomes (95% single-visit resolution rate, 70% preventive care engagement), and strengthen its competitive position as the virtual care market leader. The nationwide rollout and scale (100+ million Americans with access) demonstrate strong growth and market penetration.

#virtual care #24/7 Care service #telemedicine #preventive care #specialist consultation #prescription benefits #integrated care #Prism platform

IVECO and PlusAI launch new Level 4 Autonomous Driving programme in Spain

GlobeNewswire Inc. • Not Specified

IVECO and PlusAI launch new Level 4 Autonomous Driving programme in Spain

01/12/2026 06:00 AM • IVECO and PlusAI announced a partnership to deploy heavy-duty trucks with Level 4 autonomous driving capabilities in Southern Europe. Two IVECO S-Way vehicles equipped with PlusAI's SuperDrive virtual driver will undergo multi-year testing starting in 2026 on freight routes between Madrid and Zaragoza in Spain, in cooperation with logistics operator Sesé and the Government of Aragon.

IVCGF - IVECO is advancing its autonomous driving technology strategy through a significant partnership expansion with PlusAI, demonstrating commitment to innovation in commercial vehicles and sustainable transport solutions.

#autonomous driving #Level 4 ADS #heavy-duty trucks #IVECO S-Way #PlusAI SuperDrive #Spain #freight transportation #vehicle automation

European Wax Center, Inc. Provides Update Ahead of the 2026 ICR Conference

GlobeNewswire Inc. • Na

European Wax Center, Inc. Provides Update Ahead of the 2026 ICR Conference

01/12/2026 06:00 AM • European Wax Center, Inc. (NASDAQ: EWCZ) reported 20 net center closings in fiscal 2025, below its previous guidance of 23-28 closings, driven by timing of planned closures and progress on strategic initiatives. The company raised its fiscal 2025 financial outlook across key metrics including system-wide sales ($945-948M vs. $940-950M), total revenue ($206-208M vs. $205-209M), and adjusted EBITDA ($72-74M vs. $69-71M). Same-store sales guidance was narrowed to 0.1-0.3% growth.

QQQ - Tech sector performance closely tied to Nvidia's earnings report
EWCZ - The company beat expectations on net center closings (20 vs. 23-28 guidance) and raised its fiscal 2025 financial outlook across multiple metrics including revenue, system-wide sales, and adjusted EBITDA. Management expressed confidence in progress on strategic initiatives and the company's foundation for 2026, indicating operational improvements and better-than-expected performance.

#net center closings #fiscal 2025 outlook #system-wide sales #adjusted EBITDA #same-store sales #franchise operations #waxing services

GlobeNewswire Inc. • Na

Chief Financial Officer Transition

01/12/2026 06:00 AM • Admiral Group announces that CFO Geraint Jones will retire and transition to a part-time role from July 2026 after 24 years with the company. Rachel Lewis, currently CFO of Admiral's UK insurance business, will assume the Group CFO role and join the Board as an executive director on 1 July 2026, subject to regulatory approval. The succession follows an internal and external recruitment process.

SPY - Market sentiment depends on Nvidia's earnings and forward guidance
AMIGY - The announcement demonstrates strong succession planning with an internal promotion of an experienced executive who has been with the company for two decades. The continuity of leadership, combined with Rachel Lewis's extensive experience in financial strategy and IFRS17 implementation, suggests stability and confidence in the company's future direction. The outgoing CFO's 24-year tenure and the company's growth trajectory (market cap from £3.7B to £9.6B) further support a positive outlook.

#CFO retirement #executive succession #internal promotion #Admiral Group #leadership transition #financial management